CIPRO ORAL SUSPENSION Rx
Generic Name and Formulations:
Ciprofloxacin 5% (250mg/5mL), 10% (500mg/5mL); microcapsules for susp after reconstitution; strawberry flavor.
Indications for CIPRO ORAL SUSPENSION:
Susceptible infections, including lower respiratory tract, acute exacerbations of chronic bronchitis (AECB), skin and skin structures, bone and joint, acute sinusitis, complicated intraabdominal (w. metronidazole), UTIs, chronic bacterial prostatitis, acute uncomplicated cystitis in females. Postexposure prophylaxis and treatment of anthrax. Infectious diarrhea, typhoid fever, uncomplicated cervical and urethral gonorrhea: oral form only. Nosocomial pneumonia, empiric therapy in febrile neutropenia: IV form only. For AECB, acute sinusitis, and acute uncomplicated cystitis: reserve for those who have no alternative treatment options.
See full labeling. Swallow tabs whole, do not chew microcapsules for susp. ≥18yrs: Acute sinusitis, typhoid fever: 500mg every 12hrs for 10 days. Lower respiratory tract, skin and skin structure: 500–750mg every 12hrs for 7–14 days. Intraabdominal (w. metronidazole): 500mg every 12hrs for 7–14 days. Bone and joint: 500–750mg every 12hrs for at least 4–8 weeks. Infectious diarrhea: 500mg every 12hrs for 5–7 days. Acute uncomplicated cystitis due to E. coli, S. saprophyticus in females: 250mg every 12hrs for 3 days (oral forms only). Other UTIs: 250–500mg every 12hrs for 7–14 days. Prostatitis: 500mg every 12hrs for 28 days. Gonorrhea: 250mg once. Postexposure prophylaxis of inhalational anthrax: 500mg every 12hrs for 60 days (start as soon as possible after exposure). Treatment of inhalational, cutaneous, GI, or oropharyngeal anthrax: see CDC recommendations. Renal dysfunction (CrCl 30–50mL/min): 250–500mg every 12hrs; (CrCl 5–29mL/min): 250–500mg every 18hrs; hemo- or peritoneal dialysis: 250–500mg every 24hrs (after dialysis).
<18yrs: usually not recommended. Swallow tabs whole, do not chew microcapsules for susp. 1–17yrs: Complicated UTIs or pyelonephritis: 10–20mg/kg (max 750mg) every 12hrs for 10–21 days (see full labeling). Postexposure prophylaxis of inhalational anthrax: 15mg/kg (max 500mg/dose) every 12hrs for 60 days (start as soon as possible after exposure). Treatment of inhalational, cutaneous, GI, or oropharyngeal anthrax: see CDC recommendations.
XR not interchangeable with other forms. Increased risk of disabling and potentially irreversible adverse reactions (including tendinitis/tendon rupture [esp. in patients >60yrs, or those with kidney, heart or lung transplants], peripheral neuropathy, or CNS effects); discontinue immediately if signs/symptoms occur. CNS disorders (eg, cerebral arteriosclerosis, epilepsy) that increase seizure risk. History of myasthenia gravis; avoid. Renal (except XR tabs for uncomplicated UTIs) or hepatic dysfunction: reduce dose. History of QT prolongation, ventricular arrhythmias, proarrhythmic conditions (eg, bradycardia, acute myocardial ischemia), hypokalemia, or hypomagnesemia; avoid. Discontinue at 1st sign of skin rash, jaundice, any other hypersensitivity, phototoxicity, or hepatitis. History of joint-related disorders (esp. children). Maintain adequate hydration, avoid alkaline urine to avoid crystalluria. May mask symptoms of syphilis; test for syphilis before treating gonorrhea, then follow-up after 3 months. Monitor blood, renal, hepatic function in prolonged use. Avoid excessive sun and UV light. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
See Contraindications. Potentiates hypotensive and sedative effects of tizanidine. Avoid theophylline (increases theophylline levels), duloxetine, zolpidem; oral forms with antacids, multivalent cations, calcium, iron, zinc, sucralfate, buffered forms of didanosine, other highly buffered drugs (may give ciprofloxacin 2hrs before or 6hrs after); high ciprofloxacin doses with NSAIDs (increases seizure risk). Potentiates caffeine/xanthine derivatives. Potentiated by probenecid. Severe hypoglycemia with oral antidiabetics (eg, glyburide, glimepiride). Increased serum creatinine with cyclosporine. Monitor methotrexate, oral anticoagulants (potentiation), phenytoin (variable effects), clozapine and ropinirole (potentiation). Increased risk of tendinitis/tendon rupture with corticosteroids. Caution with sildenafil, other drugs that lower seizure threshold. Increased risk of QT prolongation with Class IA or III antiarrhythmics, TCAs, macrolides, antipsychotics. Reduced absorption with omeprazole (XR).
Nausea, diarrhea, vomiting, headache, CNS disturbances (eg, convulsions, dizziness, nervousness, insomnia, nightmares, paranoia), rash, eosinophilia, elevated liver enzymes, photosensitivity, Stevens-Johnson syndrome, myalgia, tendinitis/tendon rupture, joint-related disorders (children), local reactions (inj); rare: increased intracranial pressure, toxic psychosis; peripheral neuropathy (may be irreversible), torsades de pointes, C. difficile-associated diarrhea.
Tabs—100; Oral Susp—100mL (w. graduated teaspoon); IV premixed (100mL, 200mL)—1; XR Tabs—50, 100; IV conc—contact supplier
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Psychological Therapies May Help Older Adults With Chronic Pain
- FDA Approves First Multiple Sclerosis Treatment for Pediatric Patients
- Concussion Misdiagnosis Associated With Emergency Department Stay, Injury Type
- Vitamin D: The Only Dietary Supplement Showing Significant Benefit for MS
- Micronutrient Levels May Be Altered in ADHD
- Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying Therapy
- FDA Approves Aimovig for Migraine Prevention
- Solriamfetol Associated With Improvement in Narcolepsy Types 1 and 2
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- Unmet Therapy Needs Common in Children With Traumatic Brain Injury
- Congenital Heart Disease, Hispanic Ethnicity Associated With Increased Mortality in Pediatric Arterial Ischemic Stroke
- Addressing Migraine That Mimics Stroke
- Antidepressant Use for Insomnia: Is It Effective?
- Peripheral Neuropathy Common in Childhood Cancer Survivors